In light of the fact that the effect of CYLD-regulated cell death in DDP-sensitive cells may be regulated by other mechanism in the cells [21, 35], we explored other alternative molecular regulatory pathways that may contribute to drug resistance in ovarian cancer. Here, CYLD is linked to ovarian carcinoma.